We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
08 Jul 2026 - 10 Jul 2026

Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals

By LabMedica International staff writers
Posted on 13 Dec 2024

A complete blood count (CBC) screening is a standard examination most physicians request for healthy adults. More...

This test is essential for evaluating a patient’s overall health with a single blood sample. Currently, CBC results are interpreted using a universal reference interval, but a new study suggests this approach may overlook critical health deviations. The study, published in Nature, found that these reference intervals, or setpoints, are individualized and that one healthy patient’s CBC setpoints can differ from 98% of other healthy adults.

While CBC indices can change due to factors like genetics, medical history, and age, this new study, led by researchers from Mass General Brigham (Somerville, MA, USA), suggests that each patient has a specific “setpoint”—a baseline value around which measurements naturally fluctuate. By considering these personalized CBC setpoints, doctors could identify early-stage diseases in otherwise healthy adults, such as diabetes, heart disease, and kidney failure, which could greatly benefit from early detection and intervention.

The study demonstrated that setpoints offer a two- to four-fold relative risk stratification for several diseases, comparable to that of conventional screening methods. The researchers highlight that this discovery opens new avenues for studying how CBC thresholds vary among individuals. Additionally, the information from CBC setpoints could be used to design more targeted treatment plans and help determine whether further screening is necessary for accurate diagnosis.

“Complete blood counts are common tests, and our study suggests CBCs vary a lot from person to person even when completely healthy, and a more personalized and precision medicine approach could give more insight into a person’s health or disease,” said senior author John Higgins, MD, of the Center for Systems Biology and Department of Pathology at Massachusetts General Hospital. “The long-term stability and patient-specificity of setpoints may provide new opportunities for the personalized management of healthy adults envisioned by precision medicine.”


Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.